Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones

被引:0
|
作者
Zhang, Fan [1 ,2 ,3 ]
Li, Wenjian [1 ,4 ]
机构
[1] Xuzhou Med Univ, Changzhou Clin Coll, Changzhou, Peoples R China
[2] Changzhou Third Peoples Hosp, Dept Endocrinol, Changzhou, Peoples R China
[3] Changzhou Third Peoples Hosp, Dept Clin Nutr, Changzhou, Peoples R China
[4] Changzhou Third Peoples Hosp, Dept Urol, Changzhou, Peoples R China
来源
KIDNEY & BLOOD PRESSURE RESEARCH | 2025年 / 50卷 / 01期
关键词
Fatty liver index; Metabolic dysfunction-associated steatotic liver disease; Kidney stones; Risk factors; NHANES; BODY-MASS INDEX; NEPHROLITHIASIS; PATHOGENESIS; NAFLD;
D O I
10.1159/000543404
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: This study aimed to investigate the potential association between the fatty liver index (FLI), metabolic dysfunction-associated steatotic liver disease (MASLD), and the risk of kidney stones using large-scale population-based data. Methods: This study employed a cross-sectional design, utilizing data from the 2007 to 2018 National Health and Nutrition Examination Survey (NHANES) database. A total of 24,342 participants were enrolled in the study, and fatty liver status was assessed by calculating the FLI. MASLD was diagnosed by FLI in conjunction with cardiometabolic criteria. Data on the history of kidney stones were obtained by self-report. We employed logistic regression models to analyze the association between FLI, MASLD, and kidney stone risk and constructed multivariable adjustment models to control for potential confounders. Furthermore, we used restricted cubic spline curve models to investigate the dose-response relationship between FLI and kidney stone risk and conducted subgroup and interaction analyses. Results: The study's results indicate a strong correlation between increasing FLI quartiles and a notable rise in the prevalence of kidney stones. Specifically, the risk of developing kidney stones was 1.68 times higher among participants in the highest FLI quartile compared to those in the lowest. Furthermore, patients with MASLD exhibited a 1.35-fold increased risk of developing kidney stones compared to those with non-MASLD. Subgroup analyses demonstrated that the correlation between MASLD and kidney stone risk was consistent across multiple subgroups. However, a significant interaction was observed in the subgroups of smoking status, physical activity level, and hypertension (interaction p < 0.05). The restricted cubic spline analysis did not yield a statistically significant nonlinear association between FLI and kidney stone risk. However, the study did identify inflection point values for FLI. Conclusion: This study demonstrated an association between FLI and MASLD and the risk of kidney stones. This suggests that these conditions may be pivotal risk factors for kidney stones. Further investigation is required to elucidate these associations' underlying mechanisms and develop efficacious interventions to reduce the risk of kidney stones. Also, formulating personalized prevention and treatment strategies for different population subgroups is paramount.
引用
收藏
页码:115 / 130
页数:16
相关论文
共 50 条
  • [31] Association of daily sleep duration with risk of metabolic dysfunction-associated steatotic liver disease and adverse liver outcomes
    Wang, Qian
    Chen, Huiyi
    Deng, Huiling
    Zhang, Minyi
    Hu, Haoyue
    Ouyang, Haotong
    Ma, Lien
    Liu, Ruiyan
    Sun, Jian
    Hu, Guifang
    Wang, Kaifeng
    DIABETES & METABOLISM, 2025, 51 (03)
  • [32] Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment
    Yu, Qiang
    He, Ruixin
    Jiang, Haowen
    Wu, Ji
    Xi, Zhifeng
    He, Kang
    Liu, Yongbo
    Zhou, Tao
    Feng, Mingxuan
    Wan, Ping
    Yan, Hexin
    Xia, Qiang
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (06) : 1034 - 1041
  • [33] The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease
    Sogabe, Masahiro
    Okahisa, Toshiya
    Kagawa, Miwako
    Kashihara, Takanori
    Shinomiya, Ryo
    Miyake, Takanori
    Kawaguchi, Tomoyuki
    Yokoyama, Reiko
    Kagemoto, Kaizo
    Kida, Yoshifumi
    Okada, Yasuyuki
    Tomonari, Tetsu
    Kawano, Yutaka
    Sato, Yasushi
    Nakasono, Masahiko
    Takayama, Tetsuji
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (11-12) : 1587 - 1598
  • [34] Association between metabolic dysfunction-associated steatotic liver disease and myosteatosis measured by computed tomography
    Kim, Myung Jin
    Cho, Yun Kyung
    Kim, Eun Hee
    Lee, Min Jung
    Lee, Woo Je
    Kim, Hong-Kyu
    Jung, Chang Hee
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (05) : 1942 - 1952
  • [35] Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella
    Noureddin, Mazen
    Wei, Lai
    Castera, Laurent
    Tsochatzis, Emmanuel A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (01) : 9 - 11
  • [36] ASSOCIATION BETWEEN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND MORTALITY: A NATIONWIDE COHORT STUDY
    Kim, Gi-Ae
    Park, Yewan
    Jung, Jooyi
    HEPATOLOGY, 2024, 80 : S880 - S880
  • [37] The association between atherogenic index of plasma and metabolic dysfunction-associated fatty liver disease as detected by FibroScan
    Wang, Aili
    Li, Jialin
    Li, Li
    Ding, Huiqing
    Yang, Naibin
    Xu, Miao
    NUTRICION HOSPITALARIA, 2024, 41 (02) : 384 - 392
  • [38] Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
    Mellemkjaer, Anders
    Kjaer, Mikkel Breinholt
    Haldrup, David
    Gronbaek, Henning
    Thomsen, Karen Louise
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 28 - 34
  • [39] Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
    Zhong, Qi
    Zhou, Rui
    Huang, Yi-Ning
    Huang, Rui-Dian
    Li, Fu-Rong
    Chen, Hao-Wen
    Wei, Yan-Fei
    Liu, Kuan
    Cao, Bi-Fei
    Liao, Kai-Yue
    Xu, Zheng-Yun
    Wang, Shi-Ao
    Wu, Xian-Bo
    JOURNAL OF HEPATOLOGY, 2025, 82 (03)
  • [40] Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk
    Ionescu, Vlad Alexandru
    Gheorghe, Gina
    Bacalbasa, Nicolae
    Diaconu, Camelia Cristina
    BIOMOLECULES, 2025, 15 (02)